Charbel Chater1, Anne Bauters2, Claire Beugnet2, Lena M'Ba1, Moshe Rogosnitzky3, Philippe Zerbib1. 1. Digestive Surgery and Transplantation Unit, Hôpital Huriez, Lille University Medical Center, Lille Nord de France University, Lille, France. 2. Department of Hematology and Transfusion, Centre de Biologie et Pathologie, Lille University Medical Center, Lille, France. 3. MedInsight Research Institute, Telz-Stone, Israel.
Abstract
BACKGROUND/AIM: Colorectal cancer (CRC) is associated with high incidence and mortality rates. Carcinoembryonic antigen (CEA), a prognostic biomarker for recurrent CRC following curative resection, suffers from low sensitivity, especially in early-stage screening. Intraplatelet angiogenesis regulators (IPAR), such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), have been identified as important regulators of tumor growth in CRC. The aim of this study was to confirm the higher preoperative level of IPAR (VEGF and PDGF) in CRC patients compared to controls and to measure IPAR in CEA-negative CRC patients. METHODS: The data and blood of 30 CRC patients and 30 presumably healthy controls were prospectively analyzed and compared. RESULTS: We confirmed elevated preoperative intraplatelet VEGF and PDGF levels in CRC patients compared to controls. Importantly, IPAR were significantly elevated even in CEA-negative CRC patients. CONCLUSION: Elevated preoperative intraplatelet VEGF and PDGF levels in CRC patients suggest new possibilities for postoperative monitoring in CRC patients, especially when CEA is negative.
BACKGROUND/AIM: Colorectal cancer (CRC) is associated with high incidence and mortality rates. Carcinoembryonic antigen (CEA), a prognostic biomarker for recurrent CRC following curative resection, suffers from low sensitivity, especially in early-stage screening. Intraplatelet angiogenesis regulators (IPAR), such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), have been identified as important regulators of tumor growth in CRC. The aim of this study was to confirm the higher preoperative level of IPAR (VEGF and PDGF) in CRC patients compared to controls and to measure IPAR in CEA-negative CRC patients. METHODS: The data and blood of 30 CRC patients and 30 presumably healthy controls were prospectively analyzed and compared. RESULTS: We confirmed elevated preoperative intraplatelet VEGF and PDGF levels in CRC patients compared to controls. Importantly, IPAR were significantly elevated even in CEA-negative CRC patients. CONCLUSION: Elevated preoperative intraplatelet VEGF and PDGF levels in CRC patients suggest new possibilities for postoperative monitoring in CRC patients, especially when CEA is negative.
Authors: Gershon Y Locker; Stanley Hamilton; Jules Harris; John M Jessup; Nancy Kemeny; John S Macdonald; Mark R Somerfield; Daniel F Hayes; Robert C Bast Journal: J Clin Oncol Date: 2006-10-23 Impact factor: 44.544
Authors: M G Sciulli; P Filabozzi; S Tacconelli; R Padovano; E Ricciotti; M L Capone; M Grana; V Carnevale; P Patrignani Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2005-02 Impact factor: 4.006
Authors: Joseph E Italiano; Jennifer L Richardson; Sunita Patel-Hett; Elisabeth Battinelli; Alexander Zaslavsky; Sarah Short; Sandra Ryeom; Judah Folkman; Giannoula L Klement Journal: Blood Date: 2007-10-25 Impact factor: 22.113
Authors: Giannoula Lakka Klement; Tai-Tung Yip; Flavia Cassiola; Lena Kikuchi; David Cervi; Vladimir Podust; Joseph E Italiano; Erin Wheatley; Abdo Abou-Slaybi; Elise Bender; Nava Almog; Mark W Kieran; Judah Folkman Journal: Blood Date: 2008-11-25 Impact factor: 22.113
Authors: M J Duffy; A van Dalen; C Haglund; L Hansson; E Holinski-Feder; R Klapdor; R Lamerz; P Peltomaki; C Sturgeon; O Topolcan Journal: Eur J Cancer Date: 2007-05-18 Impact factor: 9.162
Authors: Rolando Campanella; Laura Guarnaccia; Chiara Cordiglieri; Elena Trombetta; Manuela Caroli; Giorgio Carrabba; Nicla La Verde; Paolo Rampini; Chiara Gaudino; Antonella Costa; Sabino Luzzi; Giovanna Mantovani; Marco Locatelli; Laura Riboni; Stefania Elena Navone; Giovanni Marfia Journal: Cells Date: 2020-01-25 Impact factor: 6.600
Authors: Siamack Sabrkhany; Marijke J E Kuijpers; Mirjam G A Oude Egbrink; Arjan W Griffioen Journal: Cancer Metastasis Rev Date: 2021-02-26 Impact factor: 9.264
Authors: Alessandra V S Faria; Sheila S Andrade; Maikel P Peppelenbosch; Carmen V Ferreira-Halder; Gwenny M Fuhler Journal: Cancer Metastasis Rev Date: 2020-09-01 Impact factor: 9.264